(Reuters) - Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.
Amyloidosis is a rare disease caused by an abnormal build up of a substance called amyloid in organs.
Treatment with Takeda’s Ninlaro, in combination with dexamethasone, did not show a significant improvement in patients’ overall hematologic response compared to standard of care regimens, the company said.
U.S.-listed shares of Takeda were down about 2% at $16.5 in after-hours trading.
Reporting by Manojna Maddipatla in Bengaluru; Editing by James Emmanuel